Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Barclays PLC

Barclays PLC lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 53.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 697,432 shares of the company's stock after purchasing an additional 244,278 shares during the quarter. Barclays PLC owned about 0.24% of Recursion Pharmaceuticals worth $4,596,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its position in Recursion Pharmaceuticals by 17.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company's stock valued at $12,789,000 after purchasing an additional 288,926 shares during the last quarter. FMR LLC raised its holdings in shares of Recursion Pharmaceuticals by 2.1% during the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company's stock valued at $55,116,000 after buying an additional 170,810 shares in the last quarter. State Street Corp lifted its position in Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in Recursion Pharmaceuticals in the second quarter worth approximately $5,769,000. Finally, Pier 88 Investment Partners LLC raised its stake in shares of Recursion Pharmaceuticals by 442.1% during the third quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company's stock worth $882,000 after acquiring an additional 109,210 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on RXRX shares. Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Finally, Jefferies Financial Group cut their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a research note on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Recursion Pharmaceuticals currently has an average rating of "Hold" and an average price target of $9.25.

Recursion Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ:RXRX traded down $0.06 during midday trading on Friday, reaching $6.03. The company's stock had a trading volume of 19,762,197 shares, compared to its average volume of 6,733,188. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $15.74. The firm has a market capitalization of $1.73 billion, a P/E ratio of -3.94 and a beta of 0.85. The firm has a 50 day moving average of $6.76 and a 200-day moving average of $7.19. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to analysts' expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business's quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.43) EPS. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $6.22, for a total value of $71,200.34. Following the transaction, the director now directly owns 7,098,428 shares in the company, valued at $44,152,222.16. This represents a 0.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher Gibson sold 20,000 shares of the company's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total value of $123,200.00. Following the completion of the sale, the chief executive officer now owns 762,656 shares of the company's stock, valued at $4,697,960.96. This represents a 2.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 107,788 shares of company stock worth $724,691 in the last three months. Insiders own 15.75% of the company's stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.